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Background: Preclinical evidence suggests a possible negative impact of deleterious BRCA mutations on female fertility.
However, limited and rather conflicting clinical data are available. This study assessed the reproductive potential and
performance of fertility preservation strategies in BRCA-mutated breast cancer patients.
Patients and methods: This was a retrospective analysis of two prospective studies investigating oocyte cryopreservation and
ovarian tissue cryopreservation in newly diagnosed early breast cancer patients. In the current analysis, baseline anti-Mullerian
hormone (AMH) and performance of cryopreservation strategies were compared between patients with or without germline
deleterious BRCAmutations.
Results: Out of 156 patients included, 101 had known BRCA status of whom 29 (18.6%) were BRCA-mutated and 72 (46.1%) had
no mutation. Median age in the entire cohort was 31 years [interquartile range (IQR) 28–33). Median AMH levels were 1.8 lg/l
(IQR 1.0–2.7) and 2.6 mg/l (IQR 1.5–4.1) in the BRCA-positive and BRCA-negative cohorts, respectively (P¼ 0.109). Among patients
who underwent oocyte cryopreservation (N¼ 29), women in the BRCA-positive cohort tended to retrieve (6.5 versus 9;
P¼ 0.145) and to cryopreserve (3.5 versus 6; P¼ 0.121) less oocytes than those in the BRCA-negative cohort. Poor response rate
(i.e. retrieval of4 oocytes) was 40.0% and 11.1% in the BRCA-positive and BRCA-negative cohorts, respectively (P¼ 0.147).
Among patients who underwent ovarian tissue cryopreservation (N¼ 72), women in the BRCA-positive cohort tended to have a
numerically lower number of oocytes per fragment (0.08 versus 0.14; P¼ 0.193) and per square millimeter (0.33 versus 0.78;
P¼ 0.153) than those in the BRCA-negative cohort. Two BRCA-mutated patients were transplanted after chemotherapy and one
delivered at term a healthy baby. No difference between BRCA1- and BRCA2-mutated patients was observed in any of the
above-mentioned outcomes.
Conclusion: A consistent trend for reduced reproductive potential and performance of cryopreservation strategies was
observed in BRCA-mutated breast cancer patients. Independent validation of these results is needed.
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Introduction
Over the past years, major advances in oncology practice have led
to significant survival improvements in breast cancer patients
including those diagnosed at a young age. Therefore, survivor-
ship issues are of crucial importance to be taken into account
when managing these patients [1]. Anticancer treatments in
young women with breast cancer can be associated with the
added burden of potential premature ovarian failure (POF) and
subsequent infertility [2]. As recently indicated by young women
advocates, fertility preservation is a priority area of concern for
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these patients [1]. Therefore, oncofertility counseling to discuss
POF risk and the available fertility preservation options should be
considered standard of care in all newly diagnosed young breast
cancer patients [1, 3].
Up to 8% of the cases diagnosed in young breast cancer
patients are hereditary tumors related to germline deleterious
mutations in the breast cancer susceptibility genes BRCA1 or
BRCA2; the cumulative breast cancer risk at 40 years of age is
approximately 24% for BRCA1 carriers and 13% for BRCA2 car-
riers [4]. Carrying a deleterious BRCA mutation plays a relevant
role in cancer prevention, diagnosis and treatment; furthermore,
it has been suggested to negatively impact the reproductive
potential of these women [5]. However, limited and rather con-
flicting clinical data are available to support this hypothesis.
In recent years, the role of fertility preservation strategies (such
as cryopreservation of oocytes/embryos and ovarian tissue) has
become more established and they are currently widely adopted
in young breast cancer patients [2]. Nevertheless, to date, limited
evidence exists on the reproductive potential and performance of
fertility preservation strategies in BRCA-mutated breast cancer
patients [5]. In addition, BRCA carriers face unique issues includ-
ing the consideration for prophylactic gynecological surgery at a
young age and the possible interest in preimplantation genetic
diagnosis. Therefore, in this patient population, oncofertility
counseling is particularly complex. To acquire more insights on
this unmet medical issue, we conducted the present study to eval-
uate the reproductive potential and performance of cryopreserva-
tion procedures in BRCA-mutated breast cancer patients.
Methods
Study design and participants
This is a retrospective analysis conducted within two prospective studies
that involved young women with newly diagnosed breast cancer who
underwent oocyte cryopreservation [6] or ovarian tissue cryopreservation
[7] for fertility preservation at CUB-Hoˆpital Erasme in Brussels (Belgium).
Eligible patients were premenopausal women with no history of gonado-
toxic treatments, no contraindications to surgical procedures and diagnosis
of early breast cancer at a young age (40 years for oocyte cryopreservation
and35 years for ovarian tissue cryopreservation). All patients who under-
went oocyte cryopreservation received a gonadotropin-releasing hormone
(GnRH) antagonist protocol for controlled ovarian stimulation associated
with letrozole (5mg/d) administered throughout the cycle until the day of
ovulation trigger [6].
All patients were subjected to oncofertility counseling for accessing
cryopreservation procedures shortly after breast cancer diagnosis.
Genetic susceptibility to breast cancer was known only in two patients at
the time of oncofertility counseling; for the others, genetic testing was
requested by the treating oncologists and became available at different
time points during follow-up. Therefore, genetic susceptibility did not
influence oncofertility counseling for the type of cryopreservation proce-
dure offered.
For the purpose of the present analysis, patients were divided into four
cohorts: women with deleterious BRCA1 or BRCA2 mutations (BRCA-
positive cohort), those without BRCA mutations (BRCA-negative
cohort), patients who did not undergo any genetic test (BRCA-untested
cohort) and those who underwent a genetic test but had BRCAmutations
classified as variant of unknown significance or germline mutations other
than BRCA (other-mutation cohort).
The current analysis was approved by the ethics committee and written
informed consent was obtained from all patients before study inclusion.
Study objectives
The main objectives of the present analysis were to compare the repro-
ductive potential and performance of cryopreservation procedures
between breast cancer patients with or without BRCA mutations.
Patients’ reproductive potential was assessed at the time of oncofertility
counseling (i.e. before starting anticancer treatment) by evaluating anti-
Mullerian hormone (AMH) levels. AMH was centrally performed at
CUB-Hoˆpital Erasme. The performance of fertility preservation strat-
egies was assessed by evaluating oocyte yield, cryopreserved oocytes and
poor response rate (defined as retrieval of4 oocytes) in case of oocyte
cryopreservation, and number of oocytes per fragment and number of
oocytes per square millimeter in case of ovarian tissue cryopreservation.
Preplanned subgroup analyses aimed at investigating potential differ-
ences in the reproductive potential and performance of cryopreservation
procedures between BRCA1- and BRCA2-mutated patients.
Statistical analysis
All statistical comparisons were performed between the BRCA-positive
and BRCA-negative cohorts with further descriptive details provided for
BRCA1- and BRCA2-mutated subgroups. The reproductive potential
and performance of cryopreservation procedures in the BRCA-untested
and the other-mutation cohorts were described to provide further con-
text of fertility parameters in breast cancer patients (supplementary
Tables S1–S3 and Figure S1, available atAnnals of Oncology online).
Baseline characteristics were tabulated according to BRCA status and
differences tested using chi-squared test, Fisher exact test or Wilcoxon–
Mann–Whitney test, as appropriate. To compare between characteristics
of fertility preservation strategies and their outcomes according to BRCA
status, chi-square test, Fisher exact test or Wilcoxon–Mann–Whitney test
were used, as appropriate. A logistic regression analysis was performed to
investigate the association between BRCA-mutated status and poor
response to controlled ovarian stimulation. Missing information was
consideredmissing completely at random.
All reported P values were two-sided, with values less than 0.05 consid-
ered as statistically significant. Statistical analyses were performed using
Stata 13.1 (StataCorp LP).
Results
Between January 2006 and December 2016, out of 159 breast can-
cer patients enrolled in the two prospective studies, 156 were
included in the present analysis (supplementary Figure S2, avail-
able at Annals of Oncology online). A total of 29 (18.6%) patients
had germline deleterious BRCA mutations (19 with BRCA1 and
10 with BRCA2mutations) and 72 (46.1%) had nomutations.
Median age in the entire cohort was 31 years [interquartile
range (IQR) 28–33] with no difference between the BRCA-posi-
tive and BRCA-negative cohorts. Baseline characteristics were
similar between the two cohorts with the exception of higher
mastectomy rate (53.6% versus 32.4%, P¼ 0.034), lower inci-
dence of hormone receptor–positive (24.1% versus 65.3%,
P< 0.001) and HER2-positive (6.9% versus 33.8%, P¼ 0.005)
tumors in the BRCA-positive cohort (supplementary Table S4,
available at Annals of Oncology online).
At the time of oncofertility counseling, AMH was tested in 85
patients (supplementary Figure S2, available at Annals of
Oncology online). AMH levels were strongly correlated with
patients’ age (supplementary Figure S3, available at Annals of
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Oncology online). Median AMH levels were 1.8 mg/l (IQR, 1.0–
2.7) and 2.6 mg/l (IQR, 1.5–4.1) in the BRCA-positive and BRCA-
negative cohorts, respectively (P¼ 0.109; Figure 1A). A total of 8
(32.0%) and 12 (20.0%) patients had AMH levels1mg/l in the
BRCA-positive and BRCA-negative cohorts, respectively
(P¼ 0.235). No difference was observed between BRCA1- and
BRCA2-mutated patients (Figure 1B).
A total of 29 patients underwent oocyte cryopreservation (sup
plementary Figure S2, available at Annals of Oncology online).
Patients in the BRCA-positive cohort received a numerically
higher dose of gonadotropins (2775 versus 2025 IU; P¼ 0.085)
and longer duration of stimulation (11.5 versus 9 days;
P¼ 0.110), yet they tended to retrieve (6.5 versus 9; P¼ 0.145)
and to cryopreserve (3.5 versus 6; P¼ 0.121) less oocytes than
those in the BRCA-negative cohort (Table 1). Poor response rate
was 40.0% and 11.1% in the BRCA-positive and BRCA-negative
cohorts, respectively (P¼ 0.147). The odds ratio for poor
response was 5.3 (95% confidence intervals 0.8–37.1; P¼ 0.091).
No difference in maturation rate was observed between the two
cohorts (0.8 versus 0.9; P¼ 0.888). BRCA1- and BRCA2-mutated
patients showed similar outcomes (Table 1). To date, none of the
patients who underwent oocyte cryopreservation have returned
for pursuing embryo transfer.
A total of 72 patients underwent ovarian tissue cryopreserva-
tion (supplementary Figure S2, available at Annals of Oncology
online). In more than 84% of the cases, bilateral ovarian tissue
fragments were collected. Immature oocytes were collected ex
vivo from ovarian tissue fragments before cryopreservation [7].
Patients in the BRCA-positive cohort tended to have a numeri-
cally lower number of oocytes per fragment (0.08 versus 0.14;
P¼ 0.193) and per square millimeter (0.33 versus 0.78;
P¼ 0.153) than those in the BRCA-negative cohort (Table 2).
Two patients were transplanted after chemotherapy. The first
patient was diagnosed at the age of 30 years and has a BRCA1
mutation. She was transplanted with 8 out of 17 cryopreserved
fragments of ovarian tissue grafted to the remaining ovaries
69months after chemotherapy. After preimplantation genetic
diagnosis showing that the embryo carried the mutation, the
patient decided not to proceed further with conception projects.
The second patient was diagnosed at the age of 33 and has a
BRCA2mutation. She was transplanted with 8 out of 13 cryopre-
served fragments of ovarian tissue grafted to the remaining ova-
ries 55months after chemotherapy completion. Five months
after transplantation, she had recovery of ovarian function fol-
lowed 3months later by a spontaneous pregnancy. After an
uneventful pregnancy, the patient delivered vaginally without
complications a healthy boy at term weighing 4000 g.
Discussion
To our knowledge, this is the largest comprehensive analysis
investigating fertility parameters in BRCA-mutated breast cancer
patients. We observed a consistent trend for reduced reproduc-
tive potential and performance of both oocyte and ovarian tissue
cryopreservation in the BRCA-positive cohort. These findings,
that need to be confirmed in larger ad hoc studies, should be taken
into account and may influence the oncofertility counseling of
this specific patient population.
The BRCA genes seem to be implicated in gametogenesis; as
shown in animal experiments, mice harboring BRCA mutations
may have a lower ovarian reserve and their oocytes a higher fre-
quency of nuclear abnormalities [8]. BRCA mutations lead to
impaired DNA double-strand breaks (DSBs) repair mechanism.
This can be associatedwith decreased possibility to counteract gen-
otoxic stress and subsequent potential accelerated loss of ovarian
reserve following the accumulation of DSBs in the oocytes [8].
Nevertheless, despite a strong biologic rationale supported by pre-
clinical data, limited clinical evidence exists on the possible impact
of carrying a BRCAmutation on female reproductive potential [5].
The only other study available that investigated this issue in breast
cancer patients showed significantly lower AMH levels (1.22 versus
2.23 ng/ml; P< 0.001) in BRCA carriers [9]. Similarly, we observed
a trend for lower median AMH value in the BRCA-positive cohort
(1.8 versus 2.6mg/l; P¼ 0.109). In the study by Titus and col-
leagues, BRCA1-mutated patients seemed to have lower AMH lev-
els than BRCA2 carriers (1.12 versus 1.39 ng/ml) [9]; on the
contrary, no difference was observed in our study within the
BRCA-positive cohort (1.8 versus 1.5mg/l). As recently shown in
healthy BRCA carriers [10], a possible negative impact of BRCA2
mutations on reproductive potential may be also present; never-
theless, this can be less apparent due to the delayed decline of the
normal BRCA2 allele function.
Embryo/oocyte cryopreservation is the first option for fertility
preservation to be discussed with breast cancer patients [1, 3]. Of
note, this strategy would also allow to access preimplantation
genetic diagnosis. Due to the potential increased risk of fertility-
related problems in this specific population, it has been suggested
that BRCA-mutated breast cancer patients may have a lower
response to controlled ovarian stimulation. Two single-
institution studies including a total of 32 BRCA-mutated patients
have investigated this issue. In the Israeli study, no difference in
terms of oocytes collected (11.50 versus 11.69; P¼ 0.92) was
observed between BRCA-positive and BRCA-negative breast can-
cer patients, respectively [11]. Different protocols for controlled
ovarian stimulation were used in this study and tamoxifen was
coadministered in 19% of the BRCA carriers [11]. In the
American study, all patients received a GnRH-antagonist proto-
col with the use of letrozole [12]. As compared to the BRCA-neg-
ative cohort, a lower number of collected oocytes (7.9 versus 11.3;
P¼ 0.025) and higher poor response rate (33.3% versus 3.3%;
P¼ 0.014) was observed in the BRCA-positive cohort. The low
performance of controlled ovarian stimulation was mainly
observed in BRCA1-mutated patients [12]. Similarly, in our
study, after controlled ovarian stimulation with a GnRH-
antagonist protocol that included letrozole, patients in the
BRCA-positive cohort tended to retrieve less oocytes (6.5 versus
9.0; P¼ 0.145) and to have a higher poor response rate (40.0%
versus 11.1%; P¼ 0.147) than those in the BRCA-negative
cohort. A similar performance in BRCA1- and BRCA2-mutated
patients was observed. Importantly, our study showed that the
meiotic maturation competence of the oocytes was comparable
between the BRCA-positive and BRCA-negative cohorts (0.8
versus 0.9; P¼ 0.888); this suggests that the potential accelerated
ovarian aging in BRCA-mutated patients [9] may still not be evi-
dent in young women. Acknowledging the limited data available
on the topic, although a negative impact of BRCA mutations on
the performance of controlled ovarian stimulation cannot be
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Figure 1. AMH levels (A) in the BRCA-positive and the BRCA-negative cohorts, and (B) in BRCA1- and BRCA2-mutated patients. AMH, anti-
mullerian hormone; IQR, interquartile range.
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excluded, our study confirmed that embryo/oocyte cryopreserva-
tion is feasible and remains the first fertility preservation option
to be discussed also in BRCA-mutated breast cancer patients.
Appropriate counseling is particularly important in these patients
as the chemotherapy-induced ovarian damage might be also
more pronounced [5].
Although still experimental, ovarian tissue cryopreservation is
an effective technique for fertility preservation that may be pro-
posed to selected breast cancer patients such as those who cannot
delay anticancer treatments or with contraindications to con-
trolled ovarian stimulation [2]. Our study including 19 BRCA-
mutated breast cancer patients is the largest series reporting the
Table 1. Oocyte cryopreservation in the BRCA-positive and BRCA-negative cohorts
BRCA-positive cohort (N510, 34.5%) BRCA-negative
cohort
(N5 19, 65.5%)
P valuesa
(BRCA-positive
versus
BRCA-negative)
BRCA1-positive
(N5 5, 50.0%)
BRCA2-positive
(N5 5, 50.0%)
BRCA-positive
cohort
(N5 10, 100%)
Total FSH dose (IU), median (IQR) 2775 (2700–2850) 2775 (1800–3000) 2775 (1800–3000) 2025 (1575–2425) 0.085
Type of stimulation, N (%)
Follicular 3 (60.0) 3 (60.0) 6 (60.0) 11 (57.9) 1.000
Random 2 (40.0) 2 (40.0) 4 (40.0) 8 (42.1)
Stimulation days, median (IQR) 11 (10–11) 12 (12–12) 11.5 (10–12) 9 (8–11) 0.110
E2 at trigger (pmol/l), median (IQR) 419 (95–442) 187 (159–238) 213 (95–442) 200 (92–615) 0.909
P at trigger (pmol/l), median (IQR) 1.37 (0.81–1.76) 0.45 (0.45–1.50) 1.09 (0.45–1.76) 0.84 (0.59–1.40) 0.854
Number of oocytes, median (IQR) 7 (3–7) 6 (3–7) 6.5 (3–7) 9 (5–13) 0.145
Number of mature oocytes, median (IQR) 7 (3–7) 4 (2–5) 4.5 (2–7) 7 (5–9) 0.299
Maturation rate, median (IQR) 1.0 (1.0–1.0) 0.7 (0.7–0.7) 0.8 (0.7–1.0) 0.9 (0.7–1.0) 0.888
Number of cryopreserved oocytes, median (IQR) 5 (2–7) 3 (2–4) 3.5 (2–7) 6 (4–12) 0.121
Poor response rate, N (%) 2 (40.0) 2 (40.0) 4 (40.0) 2 (11.1) 0.147
aCalculated excluding the unknown values.
FSH, follicle-stimulating hormone; IQR, interquartile range; E2, estradiol; P, progesterone.
Table 2. Ovarian tissue cryopreservation in the BRCA-positive and BRCA-negative cohorts
BRCA-positive cohort (N5 19, 26.4%) BRCA-negative
cohort
(N5 53, 73.6%)
P valuesa
(BRCA-positive
versus
BRCA-negative)
BRCA1-positive
(N5 14, 73.7%)
BRCA2-positive
(N5 5, 26.3%)
BRCA-positive
cohort
(N5 19, 100%)
Type of surgery, N (%)
Unilateral 3 (21.4) 0 (0.0) 3 (15.8) 4 (7.6) 0.371
Bilateral 11 (78.6) 5 (100) 16 (84.2) 49 (92.4)
Fragments, median (IQR) 17 (13–20) 25 (20–28) 17 (13–23) 18 (14–22) 0.913
Follicle densityb, median (IQR) 5 (3–6) 4 (3–12) 4.5 (3–7) 6 (4–10) 0.318
Not evaluated, N (%) 1 (7.1) 0 (0.0) 1 (5.3) 3 (5.7)
Number of oocytes, median (IQR) 3 (0–8) 1 (0–3) 2 (0–8) 2 (1–6) 0.682
Not collected, N (%) 7 (50) 0 (0.0) 7 (36.8) 18 (34.0)
Number of oocytes per fragment, median (IQR) 0.08 (0–0.24) 0.08 (0.03–0.20) 0.08 (0–0.24) 0.14 (0.06–0.29) 0.193
Not evaluated, N (%) 8 (57.1) 1 (20.0) 9 (47.4) 28 (52.8)
Number of oocytes per mm2, median (IQR) 0.24 (0–1.10) 0.37 (0.90–0.78) 0.33 (0–1.00) 0.78 (0.20–1.20) 0.153
Not evaluated, N (%) 8 (57.1) 1 (20.0) 9 (47.4) 28 (52.8)
Number of cryopreserved oocytes, median (IQR) 1 (0–1) 1 (0–2) 1 (0–1) 0 (0–1) 0.422
Not collected, N (%) 7 (50.0) 0 (0.0) 7 (36.8) 18 (34.0)
aCalculated excluding the unknown values.
bNumber of follicles per mm2.
IQR, interquartile range.
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performance of ovarian tissue cryopreservation in this setting.
The lower number of oocytes per fragment (0.08 versus 0.14;
P¼ 0.193) and per square millimeter (0.33 versus 0.78;
P¼ 0.153) observed in the BRCA-positive cohort are in line with
the other findings from our study suggesting a possible reduced
reproductive potential in these patients. However, the procedure
can be successful also in this setting with one out of two trans-
planted patients who had a live birth. This is the second baby
described after ovarian tissue transplantation in BRCA-mutated
breast cancer patients [13]. Due to the risk of developing ovarian
cancer, prophylactic bilateral salpingo-oophorectomy before the
age of 40 years is generally recommended in BRCA carriers [14].
Hence, ovarian tissue cryopreservation is not an optimal techni-
que in this setting. However, for most of the patients, BRCA sta-
tus is not available at the time of oncofertility counseling. In
patients who undergo ovarian tissue cryopreservation at breast
cancer diagnosis and consider to proceed to transplantation after
the end of treatment, a genetic test should be requested. In
women found to be BRCA-mutated and who are younger than
the recommended age for prophylactic bilateral salpingo-
oophorectomy, the procedure can be feasible as suggested by our
study. In this specific setting, it is recommended to transplant the
ovarian tissue only to the remaining ovaries so that the gonads
can be removed after the completion of reproductive plans. From
an ethical perspective, it remains controversial how to deal with
frozen ovarian tissue collected from patients found to be BRCA-
mutated and who are close to the recommended age for prophy-
lactic bilateral salpingo-oophorectomy. In the future, a potential
approach in this setting may be represented by in vitro growth of
isolated immature ovarian follicles without the need to undergo
ovarian tissue transplantation [5]. However, further research
efforts are needed on this regard.
Some limitations should be considered in the interpretation of
our results. This is a retrospective analysis conducted in a rela-
tively small population. Nevertheless, it was performed within
two prospective studies conducted in an institution with known
expertise in the field, and this remains the largest comprehensive
analysis available to date on this topic. Although all the results
were in the same direction suggesting a possible negative impact
of BRCA mutations on fertility parameters in line with biologic
and preclinical evidence, no statistical significance was shown
and thus no solid conclusions can be drawn. Nevertheless, this
study raises awareness about the possible need of personalized
approaches for young women with BRCA-mutated breast cancer
who are interested in pursuing fertility preservation strategies
before starting anticancer treatments.
In conclusion, our study showed that BRCA-mutated breast
cancer patients may have a reduced reproductive potential;
although feasible, fertility preservation procedures may be char-
acterized by lower performance in this setting. Considering both
that most of young women with breast cancer are nowadays can-
didates to undergo genetic testing and the widespread use of
multi-gene panel sequencing technologies in germline risk assess-
ment [15], a growing importance should be paid to fertility issues
in patients with hereditary cancer syndromes. Further larger
reproduction studies are needed to improve the oncofertility
counseling and the success of the available fertility preservation
options in this patient population.
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